High Response Rates With Larotrectinib in Tumor Types With TRK Fusions

Early-phase data on larotrectinib validate TRK fusions as therapeutic targets and show they lead to tumor-agnostic sensitivity to this agent.

Source: CancerNetwork - February 23, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Cancer and Genetics Immuno Oncology Source Type: news